1 / 13

Therapeutic Proteins and Oral Vaccines Market | CMI PR

Therapeutic proteins are proteins that are engineered in the laboratory for pharmaceutical use, including non-covalent binders, therapeutic proteins such as enzymes and albumin are having properties such as breaking of covalent bongs and therefore has wide application of treatment .Therapeutic proteins are highly effective in vivo and in-vitro treatment of diseases. Oral vaccines are biologically prepared products, which provide active acquired immunity to diseases such as cholera, polio, rotavirus, smallpox, yellow fever, and others. An oral vaccine comprise an agent resembling to the disease causing microorganism. The vaccines are generally developed from live attenuated or killed forms of the disease causing microorganism, its toxins, or its surface proteins.

dhanrajcmi
Télécharger la présentation

Therapeutic Proteins and Oral Vaccines Market | CMI PR

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ THERAPEUTIC PROTEINS AND ORAL VACCINES MARKET ANALYSIS

  2. THERAPEUTIC PROTEINS AND ORAL VACCINES MARKET ANALYSIS • Therapeutic Proteins and Oral Vaccines Market, by Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Others) and Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), by Distribution Channel Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

  3. The global therapeutic proteins and oral vaccines market size is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027). • The increasing investments by key players for the development of promising therapies for treatment of different disease conditions is expected to drive the market growth over the forecast period. For instance, in March 2020, research scientists at Migal Galilee Research Institute Ltd, the research and development center of MigVax Ltd, announced to develop a oral vaccine for a deadly coronavirus virus affecting poultry could be adapted for human use against the novel coronavirus known as 2019-nCoV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). • Moreover, increasing prevalence of oncology disease is expected to drive growth of the global therapeutic proteins and oral vaccines market. For instance, according to the World Health Organization report published in September 2018, cancer is the second leading cause of death globally, with around 70% of deaths occurring in low and middle income countries.

  4. Figure 1. Global Therapeutic Proteins and Oral Vaccines Market Value (US$ Mn), 2016-2027

  5. Global Therapeutic Proteins and Oral Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic • The increasing prevalence of COVID-19 has caused production factories to shutdown in almost all sectors, and also affected the supply of raw materials and Active Pharmaceutical Ingredients (API) of the manufacturing companies across the globe. Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of active pharmaceutical ingredients and pharmaceutical products to avoid the spread of COVID-19 and also to reduce the contamination of active pharmaceutical ingredients during the manufacturing process of pharmaceuticals products such as vaccines, tablets, and others. • According to the U.S. Food Drug and Administration’s report of June 2020, owing to the COVID-19 public health emergency, drug manufacturers are required to abide by the following current good manufacturing practice (CGMP) regulations and recommendations regarding restriction of sick employees from production areas. 1) Any employee or worker in a production unit should be medically evaluated for infectious diseases such as COVID-19. 2) If any of individual is exhibiting COVID-19 symptoms, they shall be restricted from entering the production house premises of the company to prevent contamination of drugs and active pharmaceutical ingredients (API). • Thus, the COVID-19 pandemic has negatively affected the Global therapeutic protein and oral vaccine market.

  6. In North America, increasing prevalence of cardiovascular disorders (CVDs) such as coronary heart failure and others is expected to drive the demand of therapeutic proteins for the treatment of cardiovascular diseases, which in turn is expected to boost growth of the global therapeutic proteins and oral vaccines market over the forecast period. For instance, according to the American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. suffered from some form of CVD or the after-effects of stroke. • Moreover, in Europe, increasing number of conferences and symposiums conducted in Europe, which are focused on spreading knowledge about recent advancements in biopharmaceutical field is expected to create a lucrative environment for the market growth. For instance, in September 2018, 6th European Biopharma Congress was held at Amsterdam, Netherlands. The subject of this conference was novel strategies and advancements in biopharmaceutics. Researchers and scientists participating in this seminar discussed on cell therapy, biotechnology, therapeutic biological products, gene therapy, biosimilars, drug discovery, and clinical trials. • Furthermore, Middle-to-lower income countries such as India, Indonesia, Bangladesh, Mexico, Brazil, and certain European countries do not have proper availability of biologics due to high cost and lack of reimbursement for biologics. Therefore, lower availability and affordability of biologics in middle and lower income countries are expected to hamper the biologics market growth over the forecast period.  For instance, according to article 'Affordability Issues of Biotech Drugs in Low- and Middle-Income Countries (LMICs)' published in Drug Designing and Intellectual Properties International Journal 2019, in India alone, as many as 63 million people are forced into poverty every year, owing to very high health expenses, the majority of which are out-of-pocket payments for medicines. These factors are expected to restraint the global therapeutic proteins and oral vaccines market.

  7. Figure 2. Global Therapeutic Proteins and Oral Vaccines Market Share (%) by Region, 2020

  8. Key Players • Major players operating in global therapeutic proteins and oral vaccines market include Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc

  9. Request Sample Report • Download PDF Brochure • Request Customization • Talk to Analyst • CMI Services • CMI Latest Insights • CMI Blogs • CMI Press Releases

  10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related